AI-Driven Behavioural Insights for Ozempic Drug Users

Abstract

Ozempic, a glucagon-like peptide-1 receptor agonist, has recently been found to be a transformative treatment for the management of diabetes and weight loss. This paper delves into how AI-driven behavioural and lifestyle data analytics can be integrated into the optimal outcome of Ozempic therapy. Patient data analysis can offer lifestyle recommendations, dietary adjustments, and physical activity routines with AI. This study demonstrates the possibility of AI to enhance adherence, increase therapeutic efficacy, and induce long-term health benefits. In addition, the study shows that data-driven insights can help overcome behavioural barriers, detect trends, and facilitate sustainable habits. The results show that pharmacological treatments and AI-enhanced personalized care have synergistic potential in providing comprehensive health benefits for patients with diabetes or obesity.